McKesson (MCK) Earns Daily News Sentiment Rating of 0.30
News coverage about McKesson (NYSE:MCK) has been trending positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. McKesson earned a news impact score of 0.30 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6404897379775 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- McKesson (MCK) Receives New Coverage from Analysts at Deutsche Bank (americanbankingnews.com)
- McKesson RxO Team Identifies Five Health System Pharmacy Trends to Watch in 2018 (businesswire.com)
- McKesson Corp. : MCK-US: Dividend Analysis : December 01st, 2017 (record date) : By the numbers : December 4, 2017 (finance.yahoo.com)
- McKesson Specialty Health and US Oncology Research Announce Schedule of Presentations at the 2017 American Society of Hematology Annual Meeting and Exposition (markets.financialcontent.com)
- Patient Engagement Solutions Global Market 2017: Key Players – Cerner Corporation, IBM, Epic Systems, McKesson Corporation, Medecision (medgadget.com)
Shares of McKesson (NYSE:MCK) traded down $2.40 during trading on Tuesday, hitting $150.69. 1,908,804 shares of the stock were exchanged, compared to its average volume of 1,884,408. McKesson has a twelve month low of $133.82 and a twelve month high of $169.29. The company has a current ratio of 1.05, a quick ratio of 0.61 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $30,518.58, a price-to-earnings ratio of 12.04, a price-to-earnings-growth ratio of 1.50 and a beta of 1.23.
McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, October 26th. The company reported $3.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.78 by $0.50. McKesson had a net margin of 2.24% and a return on equity of 24.87%. The business had revenue of $52.06 billion for the quarter, compared to analyst estimates of $51.69 billion. During the same period in the previous year, the business posted $2.94 earnings per share. The business’s revenue was up 4.2% compared to the same quarter last year. equities analysts forecast that McKesson will post 12.16 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 30th. This represents a $1.36 annualized dividend and a yield of 0.90%. McKesson’s payout ratio is currently 6.45%.
A number of equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $173.00 target price (down from $178.00) on shares of McKesson in a report on Wednesday, November 1st. Jefferies Group set a $165.00 target price on shares of McKesson and gave the company a “hold” rating in a report on Wednesday, October 18th. ValuEngine raised shares of McKesson from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st. BidaskClub cut shares of McKesson from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Finally, TheStreet cut shares of McKesson from a “b” rating to a “c+” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $174.31.
In other McKesson news, CEO John H. Hammergren sold 100,000 shares of the company’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $154.81, for a total transaction of $15,481,000.00. Following the transaction, the chief executive officer now directly owns 165,000 shares in the company, valued at $25,543,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John H. Hammergren sold 125,000 shares of the company’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $150.18, for a total transaction of $18,772,500.00. The disclosure for this sale can be found here. Insiders have sold 949,900 shares of company stock worth $145,403,445 over the last 90 days. 1.20% of the stock is currently owned by company insiders.
McKesson Company Profile
McKesson Corporation (McKesson) is engaged in delivering pharmaceuticals, medical supplies and healthcare information technology. The Company operates through two segments: McKesson Distribution Solutions and Technology Solutions. The McKesson Distribution Solutions segment distributes drugs and equipment, and health and beauty care products across North America and internationally.
Receive News & Ratings for McKesson Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.